Research progress and challenges of TRPV1 channel modulators as a prospective therapy for diabetic neuropathic pain

Unal-Cevik, 2021, Small fiber functionality in patients with diabetic neuropathic pain, Pain Med., 22, 2068, 10.1093/pm/pnab150 Meyer, 2006, Mechanisms of neuropathic pain, Neuron, 52, 77, 10.1016/j.neuron.2006.09.021 Peltier, 2014, Painful diabetic neuropathy, BMJ, 348, g1799, 10.1136/bmj.g1799 Attal, 2018, Diagnosis and assessment of neuropathic pain through questionnaires, Lancet Neurol., 17, 456, 10.1016/S1474-4422(18)30071-1 Feldman, 2017, New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain, Neuron, 93, 1296, 10.1016/j.neuron.2017.02.005 Colloca, 2017, Neuropathic pain, Nat. Rev. Dis. Prim., 3 Zheng, 2018, Global aetiology and epidemiology of type 2 diabetes mellitus and its complications, Nat. Rev. Endocrinol., 14, 88, 10.1038/nrendo.2017.151 Munjuluri, 2021, Capsaicin and TRPV1 channels in the cardiovascular system: the role of inflammation, Cells, 11, 18, 10.3390/cells11010018 Wang, 2021, The P2X7 receptor is involved in diabetic neuropathic pain hypersensitivity mediated by TRPV1 in the rat dorsal root ganglion, Front. Mol. Neurosci., 14, 10.3389/fnmol.2021.663649 Bujak, 2019, Inflammation, cancer and immunity-implication of TRPV1 channel, Front. Oncol., 9, 1087, 10.3389/fonc.2019.01087 Lang, 2015, Activation of TRPV1 attenuates high salt-induced cardiac hypertrophy through improvement of mitochondrial function, Br. J. Pharmacol., 172, 5548, 10.1111/bph.12987 Tanaka, 2011, Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist, Life Sci., 88, 559, 10.1016/j.lfs.2011.01.016 Koivisto, 2022, Advances in TRP channel drug discovery: from target validation to clinical studies, Nat. Rev. Drug Discov., 21, 41, 10.1038/s41573-021-00268-4 Basbaum, 2009, Cellular and molecular mechanisms of pain, Cell, 139, 267, 10.1016/j.cell.2009.09.028 Szallasi, 2007, The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept, Nat. Rev. Drug Discov., 6, 357, 10.1038/nrd2280 Caterina, 2000, Impaired nociception and pain sensation in mice lacking the capsaicin receptor, science, 288, 306, 10.1126/science.288.5464.306 Caterina, 1997, The capsaicin receptor: a heat-activated ion channel in the pain pathway, Nature, 389, 816, 10.1038/39807 Laursen, 2016, Low-cost functional plasticity of TRPV1 supports heat tolerance in squirrels and camels, Proc. Natl. Acad. Sci. U. S. A., 113, 11342, 10.1073/pnas.1604269113 Wang, 2012, Cannabinoid WIN 55,212-2 inhibits TRPV1 in trigeminal ganglion neurons via PKA and PKC pathways, Neurol. Sci., 33, 79, 10.1007/s10072-011-0620-6 Frey, 2018, TRPV1 agonist, capsaicin, induces axon outgrowth after injury via Ca(2+)/PKA signaling, eNeuro, 5, 10.1523/ENEURO.0095-18.2018 Obi, 1985, Heat induces interleukin-6 in skeletal muscle cells via TRPV1/PKC/CREB pathways, J. Appl. Physiol., 122, 683, 10.1152/japplphysiol.00139.2016 Benítez-Angeles, 2020, Structure, endogenous agonists, and mechanisms, Int. J. Mol. Sci., 21, 3421, 10.3390/ijms21103421 Fukushima, 2017, Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin, Sci. Rep., 7, 10.1038/s41598-017-12717-5 Wang, 2018, TRPV1 SUMOylation regulates nociceptive signaling in models of inflammatory pain, Nat. Commun., 9, 1529, 10.1038/s41467-018-03974-7 Gunthorpe, 2009, Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway, Drug Discov. Today, 14, 56, 10.1016/j.drudis.2008.11.005 van Nooten, 2017, Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis, Clin. Therapeut., 39, 787, 10.1016/j.clinthera.2017.02.010 Szallasi, 1999, Vanilloid (capsaicin) receptors and mechanisms, Pharmacol. Rev., 51, 159 Abdelhamid, 2013, Resiniferatoxin (RTX) causes a uniquely protracted musculoskeletal hyperalgesia in mice by activation of TRPV1 receptors, J. Pain, 14, 1629, 10.1016/j.jpain.2013.07.021 Tian, 2019, Recovery from tachyphylaxis of TRPV1 coincides with recycling to the surface membrane, Proc. Natl. Acad. Sci. U. S. A., 116, 5170, 10.1073/pnas.1819635116 Schiano Moriello, 2018, Elongation of the hydrophobic chain as a molecular switch: discovery of capsaicin derivatives and endogenous lipids as potent transient receptor potential vanilloid channel 2 antagonists, J. Med. Chem., 61, 8255, 10.1021/acs.jmedchem.8b00734 Thorat, 2021, Discovery of benzopyridone-based transient receptor potential vanilloid 1 agonists and antagonists and the structural elucidation of their activity shift, J. Med. Chem., 64, 370, 10.1021/acs.jmedchem.0c00982 Caterina, 2008, On the thermoregulatory perils of TRPV1 antagonism, Pain, 136, 3, 10.1016/j.pain.2008.02.033 Pumroy, 2020, Structural insights into the gating mechanisms of TRPV channels, Cell Calcium, 87, 10.1016/j.ceca.2020.102168 Luo, 2019, Molecular basis for heat desensitization of TRPV1 ion channels, Nat. Commun., 10, 2134, 10.1038/s41467-019-09965-6 Garami, 2020, Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis, Pharmacol. Ther., 208, 10.1016/j.pharmthera.2020.107474 Steiner, 2007, Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors, J. Neurosci., 27, 7459, 10.1523/JNEUROSCI.1483-07.2007 Manitpisitkul, 2016, TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study, Pain Rep., 1, e576, 10.1097/PR9.0000000000000576 Garami, 2010, Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia, J. Neurosci., 30, 1435, 10.1523/JNEUROSCI.5150-09.2010 Zhong, 2019, TRPV1 mediates glucose-induced insulin secretion through releasing neuropeptides, 33, 1431 Waluk, 2013, N-Acyl taurines trigger insulin secretion by increasing calcium flux in pancreatic β-cells, Biochem. Biophys. Res. Commun., 430, 54, 10.1016/j.bbrc.2012.11.026 Akiba, 2004, Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats, Biochem. Biophys. Res. Commun., 321, 219, 10.1016/j.bbrc.2004.06.149 Gram, 2017, TRPV1: a potential therapeutic target in type 2 diabetes and comorbidities?, Trends Mol. Med., 23, 1002, 10.1016/j.molmed.2017.09.005 Jeong, 2018, Activation of temperature-sensitive TRPV1-like receptors in ARC POMC neurons reduces food intake, PLoS Biol., 16, 10.1371/journal.pbio.2004399 Razavi, 2006, TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes, Cell, 127, 1123, 10.1016/j.cell.2006.10.038 Wei, 2020, Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes, Metabolism, 105, 10.1016/j.metabol.2020.154182 Luo, 2012, TRPV1 activation improves exercise endurance and energy metabolism through PGC-1alpha upregulation in mice, Cell Res., 22, 551, 10.1038/cr.2011.205 Vahidi Ferdowsi, 2021, TRPV1 activation by capsaicin mediates glucose oxidation and ATP production independent of insulin signalling in mouse skeletal muscle cells, Cells, 10, 1560, 10.3390/cells10061560 Li, 2013, Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor delta activation, Pflügers Archiv, 465, 1303, 10.1007/s00424-013-1274-4 Baskaran, 2017, TRPV1 activation counters diet-induced obesity through sirtuin-1 activation and PRDM-16 deacetylation in Brown adipose tissue, Int. J. Obes., 41, 739, 10.1038/ijo.2017.16 Gao, 2020, Inhibition of mitochondrial calcium overload by SIRT3 prevents obesity- or age-related whitening of Brown adipose tissue, Diabetes, 69, 165, 10.2337/db19-0526 Kawabata, 2009, Non-pungent capsaicin analogs (capsinoids) increase metabolic rate and enhance thermogenesis via gastrointestinal TRPV1 in mice, Biosci. Biotechnol. Biochem., 73, 2690, 10.1271/bbb.90555 Gram, 2019, TRPV1 antagonists as novel anti-diabetic agents: regulation of oral glucose tolerance and insulin secretion through reduction of low-grade inflammation?, Med. Sci. (Basel), 7, 82 Li, 2022, Lack of TRPV1 aggravates obesity-associated hypertension through the disturbance of mitochondrial Ca2+ homeostasis in brown adipose tissue, Hypertens. Res., 45, 789, 10.1038/s41440-021-00842-8 Page, 2019, The TRPV1 channel regulates glucose metabolism, Am. J. Physiol. Endocrinol. Metab., 317, E667, 10.1152/ajpendo.00102.2019 Sloan, 2021, Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy, Nat. Rev. Endocrinol., 17, 400, 10.1038/s41574-021-00496-z Rosenberger, 2020, Challenges of neuropathic pain: focus on diabetic neuropathy, J. Neural. Transm. (Vienna), 127, 589, 10.1007/s00702-020-02145-7 Florkowski, 1991, Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy, Diabetes, 40, 129, 10.2337/diab.40.1.129 Bolcskei, 2005, Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice, Pain, 117, 368, 10.1016/j.pain.2005.06.024 Zhou, 2018, Suppressing PKC-dependent membrane P2X3 receptor upregulation in dorsal root ganglia mediated electroacupuncture analgesia in rat painful diabetic neuropathy, Purinergic Signal., 14, 359, 10.1007/s11302-018-9617-4 Jiang, 2019, IL-35 alleviates inflammation progression in a rat model of diabetic neuropathic pain via inhibition of JNK signaling, J. Inflamm., 16, 19, 10.1186/s12950-019-0217-z Sleczkowska, 2022, Peripheral ion channel gene screening in painful- and painless-diabetic neuropathy, Int. J. Mol. Sci., 23, 7190, 10.3390/ijms23137190 Dozio, 2021, Glycation and glycosylation in cardiovascular remodeling: focus on advanced glycation end products and O-linked glycosylations as glucose-related pathogenetic factors and disease markers, J. Clin. Med., 10, 4792, 10.3390/jcm10204792 Aghazadeh Tabrizi, 2017, Medicinal chemistry, pharmacology, and clinical implications of TRPV1 receptor antagonists, Med. Res. Rev., 37, 936, 10.1002/med.21427 Baron, 2010, Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment, Lancet, 9, 808 Duzova, 2021, Noopept attenuates diabetes-mediated neuropathic pain and oxidative hippocampal neurotoxicity via inhibition of TRPV1 channel in rats, Mol. Neurobiol., 58, 5031, 10.1007/s12035-021-02478-8 Jani, 2021, Distinct mechanisms involving diacylglycerol, ceramides, and inflammation underlie insulin resistance in oxidative and glycolytic muscles from high fat-fed rats, Sci. Rep., 11, 10.1038/s41598-021-98819-7 Xing, 2019, MZF1 in the dorsal root ganglia contributes to the development and maintenance of neuropathic pain via regulation of TRPV1, Neural Plast., 10.1155/2019/2782417 Zhang, 2020, Alpha-lipoic acid downregulates TRPV1 receptor via NF-kappaB and attenuates neuropathic pain in rats with diabetes, CNS Neurosci. Ther., 26, 762, 10.1111/cns.13303 Staaf, 2009, Differential regulation of TRP channels in a rat model of neuropathic pain, Pain, 144, 187, 10.1016/j.pain.2009.04.013 Li, 2017, Analgesic effect of coumarins from Radix angelicae pubescentis is mediated by inflammatory factors and TRPV1 in a spared nerve injury model of neuropathic pain, J. Ethnopharmacol., 195, 81, 10.1016/j.jep.2016.11.046 Xie, 2022, GPR177 in A-fiber sensory neurons drives diabeticneuropathic pain via WNT-media, Sci. Transl. Med., 14, 10.1126/scitranslmed.abh2557 Shuba, 2020, Beyond neuronal heat sensing: diversity of TRPV1 heat-capsaicin receptor-channel functions, Front. Cell. Neurosci., 14 Carrasco, 2018, Neuropathic pain: delving into the oxidative origin and the possible implication of transient receptor potential channels, Front. Physiol., 9, 95, 10.3389/fphys.2018.00095 Fernandez-Carvajal, 2020, Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels, Expet Opin. Invest. Drugs, 29, 1209, 10.1080/13543784.2020.1825680 Liu, 2018, Long non-coding RNA BC168687 is involved in TRPV1-mediated diabetic neuropathic pain in rats, Neuroscience, 374, 214, 10.1016/j.neuroscience.2018.01.049 Barton, 2006, Attenuation of experimental arthritis in TRPV1R knockout mice, Exp. Mol. Pathol., 81, 166, 10.1016/j.yexmp.2006.04.007 Luo, 2018, Zinc inhibits TRPV1 to alleviate chemotherapy-induced neuropathic pain, J. Neurosci., 38, 474, 10.1523/JNEUROSCI.1816-17.2017 Frank, 2020, In vivo photopharmacology enabled by multifunctional fibers, ACS Chem. Neurosci., 11, 3802, 10.1021/acschemneuro.0c00577 Luo, 2020, Network pharmacology in research of Chinese medicine formula: methodology, application and prospective, Chin. J. Integr. Med., 26, 72, 10.1007/s11655-019-3064-0 Abbas, 2020, Modulation of TRPV1 channel function by natural products in the treatment of pain, Chem. Biol. Interact., 330, 10.1016/j.cbi.2020.109178 Ha, 2022, Lotus seed green embryo extract and a purified glycosyloxyflavone constituent, narcissoside, activate TRPV1 channels in dorsal root ganglion sensory neurons, J. Agric. Food Chem., 70, 3969, 10.1021/acs.jafc.1c07724 Eom, 2021, Antioxidative and analgesic effects of naringin through selective inhibition of transient receptor potential vanilloid member 1, Antioxidants, 11, 64, 10.3390/antiox11010064 Huang, 2022, Highly oxygenated dimeric grayanane diterpenoids as analgesics TRPV1 and TRPA1 dual antagonists from Rhododendron molle, Chin. J. Chem., 40, 2285, 10.1002/cjoc.202200348 Kossakowski, 2019, Cannabidiol affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 receptors and has peripheral sympathomimetic effects in spontaneously hypertensive and normotensive rats, Front. Pharmacol., 10, 500, 10.3389/fphar.2019.00500 Journigan, 2021, Structural and in vitro functional characterization of a menthyl TRPM8 antagonist indicates species-dependent regulation, ACS Med. Chem. Lett., 12, 758, 10.1021/acsmedchemlett.1c00001 Naik, 2022, Natural products and some semi-synthetic analogues as potential TRPV1 ligands for attenuating neuropathic pain, Curr. Pharmaceut. Biotechnol., 23, 766, 10.2174/1389201022666210719155931 Gao, 2021, A patent review of transient receptor potential vanilloid type 1 modulators (2014-present), Expert Opin. Ther. Pat., 31, 169, 10.1080/13543776.2021.1854225 Winter, 1995, Capsaicin and pain mechanisms, Br. J. Anaesth., 75, 157, 10.1093/bja/75.2.157 Kulkantrakorn, 2019, 0.075% capsaicin lotion for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial, J. Clin. Neurosci., 62, 174, 10.1016/j.jocn.2018.11.036 Treat, 2022, Novel TRPV1 modulators with reduced pungency induce analgesic effects in mice, ACS Omega, 7, 2929, 10.1021/acsomega.1c05727 Brown, 2015, Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain, Pain, 156, 1018, 10.1097/j.pain.0000000000000115 Sharma, 2019, A sensitive bioanalytical method for quantitative determination of resiniferatoxin in rat plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and its application in pharmacokinetic study, J. Pharm. Biomed. Anal., 165, 284, 10.1016/j.jpba.2018.12.024 Zhai, 2019, Pharmacokinetic effects of capsaicin on vinblastine in rats mediated by CYP3A and Mrp2, Fundam. Clin. Pharmacol., 33, 376, 10.1111/fcp.12448 Iadarola, 2011, The vanilloid agonist resiniferatoxin for interventional-based pain control, Curr. Top. Med. Chem., 11, 2171, 10.2174/156802611796904942 Kwon, 2022, Vanilloid-dependent TRPV1 opening trajectory from cryoEM ensemble analysis, Nat. Commun., 13, 2874, 10.1038/s41467-022-30602-2 Singla, 2020, Regulation of pain genes-capsaicin vs resiniferatoxin: reassessment of transcriptomic data, Front. Pharmacol., 11, 10.3389/fphar.2020.551786 Burness, 2016, Capsaicin 8 % patch: a review in peripheral neuropathic pain, Drugs, 76, 123, 10.1007/s40265-015-0520-9 Loryan, 2012, Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia, Eur. J. Clin. Pharmacol., 68, 397, 10.1007/s00228-011-1132-2 Ann, 2020, Discovery of nonpungent transient receptor potential vanilloid 1 (TRPV1) agonist as strong topical analgesic, J. Med. Chem., 63, 418, 10.1021/acs.jmedchem.9b01046 Martel-Pelletier, 2012, Future therapeutics for osteoarthritis, Bone, 51, 297, 10.1016/j.bone.2011.10.008 Newswire, 2021 Salem, 2021, Resiniferatoxin hampers the nocifensive response of Caenorhabditis elegans to noxious heat, and pathway analysis revealed that the Wnt signaling pathway is involved, Neurochem. Res., 47, 622, 10.1007/s11064-021-03471-2 Rottey, 2022, Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors, Clin. Cancer Res., 28, 95, 10.1158/1078-0432.CCR-21-1181 McLellan, 2013 Dulsat, 2017, American academy of neurology - 69th annual meeting (April22-28, 2017 -Boston, Massachusetts, USA), Drug of today, 53, 309, 10.1358/dot.2017.53.5.2646003 Iftinca, 2021, TRPV1-Targeted drugs in development for human pain conditions, Drugs, 81, 7, 10.1007/s40265-020-01429-2 Lee, 2015, Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 -- 2014), Expert Opin. Ther. Pat., 25, 291, 10.1517/13543776.2015.1008449 Bevan, 1992, Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin, Br. J. Pharmacol., 107, 544, 10.1111/j.1476-5381.1992.tb12781.x Belvisi, 1992, Capsazepine as a selective antagonist of capsaicin-induced activation of C-fibres in Guinea-pig bronchi, Eur. J. Pharmacol., 215, 341, 10.1016/0014-2999(92)90054-8 Bevan, 1992, Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin, Br. J. Pharmacol., 197, 544, 10.1111/j.1476-5381.1992.tb12781.x Park, 2004, N-4-Substituted-benzyl-N'-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity, Bioorg. Med. Chem. Lett., 14, 787, 10.1016/j.bmcl.2003.11.019 Jakab, 2005, Pharmacological characterization of the TRPV1 receptor antagonist JYL1421 (SC0030) in vitro and in vivo in the rat, Eur. J. Pharmacol., 517, 35, 10.1016/j.ejphar.2005.05.002 Toth, 2004, Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population, Mol. Pharmacol., 65, 282, 10.1124/mol.65.2.282 Chang, 2010, Silicon switch approach in TRPV1 antagonist MK-056 and its analogues, Bioorg. Med. Chem., 18, 111, 10.1016/j.bmc.2009.11.014 More, 2020, Effect of TRPV1 antagonist SC0030, a potent painkiller, on RANKL-mediated osteoclast differentiation involved in bone resorption, Bull. Kor. Chem. Soc., 41, 488, 10.1002/bkcs.11992 Miranda, 2007, The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis, Neuroscience, 148, 1021, 10.1016/j.neuroscience.2007.05.034 Tang, 2007, Antinociceptive pharmacology of N-(4-chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea, a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor, J. Pharmacol. Exp. Therapeut., 321, 791, 10.1124/jpet.106.117572 Lee, 2003, N-(3-Acyloxy-2-benzylpropyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor, J. Med. Chem., 46, 3116, 10.1021/jm030089u Lee, 2004, N-[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: analysis of structure-activity relationships for the "C-Region, Bioorg. Med. Chem., 12, 371, 10.1016/j.bmc.2003.10.047 Heber, 2020, TRPV1 antagonist BCTC inhibits pH 6.0-induced pain in human skin, Pain, 161, 1532, 10.1097/j.pain.0000000000001848 Chen, 2014, Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel, J. Biol. Chem., 289, 9600, 10.1074/jbc.M113.536862 Ognyanov, 2006, Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-Piperazin-1-yl-1H-benzimidazoles, J. Med. Chem., 49, 3719, 10.1021/jm060065y Abram, 2017, Multifunctional hybrid compounds derived from 2-(2,5-Dioxopyrrolidin-1-yl)-3-methoxypropanamides with anticonvulsant and antinociceptive properties, J. Med. Chem., 60, 8565, 10.1021/acs.jmedchem.7b01114 Abram, 2020, Multitargeted compounds derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-acetamides as candidates for effective anticonvulsant and antinociceptive agents, ACS Chem. Neurosci., 11, 1996, 10.1021/acschemneuro.0c00257 Liang, 2022, Discovery of potent and selective transient receptor potential vanilloid 1 (TRPV1) agonists with analgesic effects in vivo based on the functional conversion induced by altering the orientation of the indazole core, J. Med. Chem., 65, 11658, 10.1021/acs.jmedchem.2c00469 Liao, 2018, Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carbo xamide, Bioorg. Med. Chem., 26, 845, 10.1016/j.bmc.2017.12.048 Liu, 2018, Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1, Bioorg. Med. Chem., 26, 4567, 10.1016/j.bmc.2018.08.002 Wang, 2015, Evaluation of anti-inflammatory and analgesic effects of synthesized derivatives of ibuprofen, Chem. Biol. Drug Des., 85, 623, 10.1111/cbdd.12316 Yan, 2016, Synthesis of analogues of BCTC incorporating a pyrrolidinyl linker and biological evaluation as transient receptor potential vanilloid 1 antagonists, Chem. Biol. Drug Des., 87, 306, 10.1111/cbdd.12661 Hu, 2021, Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists, Bioorg. Chem., 115, 10.1016/j.bioorg.2021.105229 Park, 2005, Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands, Bioorg. Med. Chem. Lett., 15, 631, 10.1016/j.bmcl.2004.11.033 Fletcher, 2006, The search for novel TRPV1-antagonists: from carboxamides to benzimidazoles and indazolones, Bioorg. Med. Chem. Lett., 16, 2872, 10.1016/j.bmcl.2006.03.004 Xi, 2005, Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists, Bioorg. Med. Chem. Lett., 15, 5211, 10.1016/j.bmcl.2005.08.100 Jetter, 2008, N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1), Bioorg. Med. Chem. Lett., 18, 2730, 10.1016/j.bmcl.2008.02.075 Kang, 2021, 2-(Halogenated Phenyl) acetamides and propanamides as potent TRPV1 antagonists, Bioorg. Med. Chem. Lett., 48, 10.1016/j.bmcl.2021.128266 Serafini, 2018, Targeting transient receptor potential vanilloid 1 (TRPV1) channel softly: the discovery of passerini adducts as a topical treatment for inflammatory skin disorders, J. Med. Chem., 61, 4436, 10.1021/acs.jmedchem.8b00109 Kim, 2012, 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region, J. Med. Chem., 55, 8392, 10.1021/jm300780p Lee, 2017, J. Lee, t-Butyl pyridine and phenyl C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists, Bioorg. Med. Chem., 25, 2451, 10.1016/j.bmc.2017.03.004 Lee, 2017, Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists, Bioorg. Med. Chem. Lett., 27, 4383, 10.1016/j.bmcl.2017.08.020 Almaghrabi, 2016, Inhibition of platelet aggregation by vanilloid-like agents is not mediated by transient receptor potential vanilloid-1 channels or cannabinoid receptors, Clin. Exp. Pharmacol. Physiol., 43, 606, 10.1111/1440-1681.12569 Gunthorpe, 2007, Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor, J. Pharmacol. Exp. Therapeut., 321, 1183, 10.1124/jpet.106.116657 Othman, 2013, Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/pharmacodynamic analysis of three phase 1 trials, Br. J. Clin. Pharmacol., 75, 1029, 10.1111/j.1365-2125.2012.04405.x Kang, 2020, Discovery of 1-(1H-indazol-4-yl)-3-((1-phenyl-1H-pyrazol-5-yl)methyl) ureas as potent and thermoneutral TRPV1 antagonists, Bioorg. Med. Chem. Lett., 30, 10.1016/j.bmcl.2020.127548 Perner, 2007, In vitro structure-activity relationship and in vivo characterization of 1-(Aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists, J. Med. Chem., 50, 3651, 10.1021/jm070276i Gomtsyan, 2005, Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties, J. Med. Chem., 48, 744, 10.1021/jm0492958 Gao, 2019, Design, synthesis and biological evaluation of N(1)-(isoquinolin-5-yl)-N(2)-phenylpyrrolidine-1,2-dicarboxamide derivatives as potent TRPV1 antagonists, Bioorg. Chem., 82, 100, 10.1016/j.bioorg.2018.09.033 Lee, 2019, Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain, Eur. J. Med. Chem., 182, 10.1016/j.ejmech.2019.111634 Qiao, 2022, Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist, Eur. J. Med. Chem., 233, 10.1016/j.ejmech.2022.114191 Urbahns, 2011, Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence, Bioorg. Med. Chem. Lett., 21, 3354, 10.1016/j.bmcl.2011.04.013 Urbahns, 2012, Tetrahydro-naphthols as orally available TRPV1 inhibitors, Bioorg. Med. Chem. Lett., 22, 3408, 10.1016/j.bmcl.2012.03.108 Sun, 2015, 6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists, Bioorg. Med. Chem. Lett., 25, 803, 10.1016/j.bmcl.2014.12.086 Tafesse, 2014 Beider, 2020, Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response, J. Hematol. Oncol., 13, 158, 10.1186/s13045-020-00993-0 Norman, 2007, Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides, J. Med. Chem., 50, 3497, 10.1021/jm070189q Xiao, 2019, The investigation of allosteric regulation mechanism of analgesic effect using SD rat taste bud tissue biosensor, Biosens. Bioelectron., 126, 815, 10.1016/j.bios.2018.11.046 Li, 2019, Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists, Eur. J. Med. Chem., 178, 433, 10.1016/j.ejmech.2019.06.007 Kort, 2012, TRPV1 antagonists: clinical setbacks and prospects for future development, Prog. Med. Chem., 51, 57, 10.1016/B978-0-12-396493-9.00002-9 Szallasi, 2008, Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists, Expert Opin. Ther. Pat., 18, 159, 10.1517/13543776.18.2.159 Voight, 2014, Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)ur ea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy, J. Med. Chem., 57, 7412, 10.1021/jm500916t Brederson, 2013, Targeting TRP channels for pain relief, Eur. J. Pharmacol., 716, 61, 10.1016/j.ejphar.2013.03.003 Arsenault, 2018, NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain, Pain Rep., 3, e696, 10.1097/PR9.0000000000000696 Lee, 2019, Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial, Br. J. Dermatol., 180, 1030, 10.1111/bjd.17455 Kitagawa, 2013, JTS-653 blocks afferent nerve firing and attenuates bladder overactivity without affecting normal voiding function, J. Urol., 189, 1137, 10.1016/j.juro.2012.09.055 Wang, 2020, TRPV1 antagonist DWP05195 induces ER stress-dependent apoptosis through the ROS-p38-CHOP pathway in human ovarian cancer cells, Cancers (Basel), 12, 1702, 10.3390/cancers12061702 Belvisi, 2017, XEN-D0501, a novel TRPV1 antagonist, does not reduce cough in refractory cough patients, Am. J. Respir. Crit. Care Med., 196, 1255, 10.1164/rccm.201704-0769OC https://clinicaltrials.gov/ct2/show/NCT02961062. Gibson, 2014, A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers, PLoS One, 9, 10.1371/journal.pone.0100610 Hai, 2020, Intragastric administration of AMG517, a TRPV1 antagonist, enhanced activity-dependent energy metabolism via capsaicin-sensitive sensory nerves in mice, Biosci. Biotechnol. Biochem., 84, 2121, 10.1080/09168451.2020.1789836 Eid, 2011, Therapeutic targeting of TRP channels - the TR(i)P to pain relief, Curr. Top. Med. Chem., 11, 2118, 10.2174/156802611796904898 Rowbotham, 2011, Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial, Pain, 152, 1192, 10.1016/j.pain.2011.01.051 Charrua, 2009, GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models, J. Urol., 181, 379, 10.1016/j.juro.2008.08.121 Quiding, 2013, TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction, Pain, 154, 808, 10.1016/j.pain.2013.02.004 Kitagawa, 2012, Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyrid in-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist, J. Pharmacol. Exp. Therapeut., 342, 520, 10.1124/jpet.112.194027 Lee, 2017, A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers, Drug Des. Dev. Ther., 11, 1301, 10.2147/DDDT.S128727 Lee, 2018, A novel, topical, nonsteroidal, TRPV1 antagonist, PAC-14028 cream improves skin barrier function and exerts anti-inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis, J. Dermatol. Sci., S0923–1811 Arendt-Nielsen, 2016, A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile, Pain, 157, 2057, 10.1097/j.pain.0000000000000610 Round, 2011, An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects, Br. J. Clin. Pharmacol., 72, 921, 10.1111/j.1365-2125.2011.04040.x Manitpisitkul, 2018, A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep), Scand. J. Pain, 18, 151, 10.1515/sjpain-2017-0184 Brown, 2017, Safety, pharmacokinetics, and pharmacodynamics study in healthy subjects of oral NEO6860, a modality selective transient receptor potential vanilloid subtype 1 antagonist, J. Pain, 18, 726, 10.1016/j.jpain.2017.01.009 Benitez-Del-Castillo, 2016, Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease, Invest. Ophthalmol. Vis. Sci., 57, 6447, 10.1167/iovs.16-20303 Gomtsyan, 2015 Stasi, 2021, Topical ocular TRPV1 antagonist SAF312 was well tolerated and effectively reduced pain after photorefractive keratectomy (PRK), Ann. Meet Assoc. Res. Vis. Ophthalmol. (ARVO), 62